After obtaining his degree in Biochemistry and Applied Clinical Biochemistry from UMIST in 2001, Andrew completed a PhD in Molecular Parasitology from the University of Manchester, studying the folate biosynthetic pathway of the malaria parasite Plasmodium falciparum. In 2006 he joined the Sinden lab at Imperial College, London, to study the sexual stages of Plasmodium, with an emphasis on developing transmission-blocking interventions (TBIs) to target the parasite within the mosquito host, inhibiting or preventing the onward transmission of malaria. He is currently a Principal Investigator in the DoLS, and his main interests focus on the identification of novel anti-malarial transmission blocking vaccine targets, vaccine delivery, the development of assays to examine TBI efficacy, and assessing the practical impact of introducing TBIs on populations of mosquitoes and vertebrate in both the laboratory and the field.
et al., 2017, Probability of Transmission of Malaria from Mosquito to Human Is Regulated by Mosquito Parasite Density in Naive and Vaccinated Hosts, Plos Pathogens, Vol:13, ISSN:1553-7366
et al., 2017, Antimalarial efficacy of MMV390048, an inhibitor of Plasmodium phosphatidylinositol 4-kinase, Science Translational Medicine, Vol:9, ISSN:1946-6234
et al., 2017, A novel model fitted to multiple life stages of malaria for assessing efficacy of transmission-blocking interventions, Malaria Journal, Vol:16, ISSN:1475-2875
et al., 2016, A novel multiple-stage antimalarial agent that inhibits protein synthesis (vol 522, pg 315, 2015), Nature, Vol:537, ISSN:0028-0836, Pages:122-122
et al., 2016, Tailoring a Combination Preerythrocytic Malaria Vaccine, Infection and Immunity, Vol:84, ISSN:0019-9567, Pages:622-634